{"id":{"repo_id":"milano","oai_identifier":"oai:air.unimi.it:2434/1157078"},"canonical_url":"https://search.dev.ndltd.org/etd/milano/oai:air.unimi.it:2434/1157078","repository":{"repo_id":"milano","name":"Università degli Studi di Milano","base_url":"https://air.unimi.it/oai/request"},"display":{"title":"INFLAMMATORY AND T-CELL HOMEOSTASIS PARAMETERS IN DUAL AND TRIPLE COMBINATION ANTIRETROVIRAL THERAPY (CART) FOR HIV INFECTION","abstract":"Primary HIV infection (PHI) plays a pivotal role in establishing the viral reservoir, leading to persistent immune activation and inflammation despite combination antiretroviral therapy (cART). While cART has transformed HIV into a manageable chronic condition, it remains unable to eradicate the virus or fully restore immune homeostasis. This study explores two critical aspects of HIV management: (i) the impact of early cART initiation during PHI on inflammation, immune activation, and microbial translocation, and (ii) the effects of innovative therapeutic strategies, including dual cART regimens and long-acting injectable treatments, on immune regulation and T-cell homeostasis. The research is structured around three key objectives: (1) investigating the HIV reservoir, circulating Th1/Th2 cytokines, gut integrity, and microbial translocation in individuals with PHI and chronic HIV infection (CHI) before and after cART initiation; (2) assessing immune parameters, gut barrier dysfunction, and mitochondrial stress in PLWH switching from triple to dual INSTI-based cART; and (3) evaluating T-cell homeostasis and activation in virally suppressed individuals transitioning to the long-acting injectable regimen cabotegravir plus rilpivirine (CAB+RPV). By providing deeper insights into how different treatment strategies affect immune activation and inflammation, this study aims to refine therapeutic approaches and mitigate long-term complications in people living with HIV.","abstract_html":"Primary HIV infection (PHI) plays a pivotal role in establishing the viral reservoir, leading to persistent immune activation and inflammation despite combination antiretroviral therapy (cART). While cART has transformed HIV into a manageable chronic condition, it remains unable to eradicate the virus or fully restore immune homeostasis. This study explores two critical aspects of HIV management: (i) the impact of early cART initiation during PHI on inflammation, immune activation, and microbial translocation, and (ii) the effects of innovative therapeutic strategies, including dual cART regimens and long-acting injectable treatments, on immune regulation and T-cell homeostasis. The research is structured around three key objectives: (1) investigating the HIV reservoir, circulating Th1/Th2 cytokines, gut integrity, and microbial translocation in individuals with PHI and chronic HIV infection (CHI) before and after cART initiation; (2) assessing immune parameters, gut barrier dysfunction, and mitochondrial stress in PLWH switching from triple to dual INSTI-based cART; and (3) evaluating T-cell homeostasis and activation in virally suppressed individuals transitioning to the long-acting injectable regimen cabotegravir plus rilpivirine (CAB+RPV). By providing deeper insights into how different treatment strategies affect immune activation and inflammation, this study aims to refine therapeutic approaches and mitigate long-term complications in people living with HIV.","abstract_has_math":false,"creators":["BONO, VALERIA"],"institution":"Università degli Studi di Milano","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["tutor: C. Tincati : revisori: M. Lichtner","G. Madeddu; coordinatore: M. Clerici","C. Sforza","V. Bono","TINCATI, CAMILLA","SFORZA, CHIARELLA","CLERICI, MARIO SALVATORE"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025-03-25","date_published":"2025-03-25","updated_at":"2026-07-27T20:19:05Z","subjects":["Settore MEDS-10/B - Malattie infettive"],"languages":["eng"],"rights":["info:eu-repo/semantics/openAccess"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["http://dx.doi.org/10.13130/bono-valeria_phd2025-03-25","10.13130/bono-valeria_phd2025-03-25"],"render_values":[{"text":"http://dx.doi.org/10.13130/bono-valeria_phd2025-03-25","href":"http://dx.doi.org/10.13130/bono-valeria_phd2025-03-25","code":true},{"text":"10.13130/bono-valeria_phd2025-03-25","href":"https://doi.org/10.13130/bono-valeria_phd2025-03-25","code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/2434/1157078","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["tutor: C. Tincati : revisori: M. Lichtner","G. Madeddu; coordinatore: M. Clerici","C. Sforza","V. Bono","TINCATI, CAMILLA","SFORZA, CHIARELLA","CLERICI, MARIO SALVATORE"]},{"key":"dc:creator","label":"Author","values":["BONO, VALERIA"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2025-03-25"]},{"key":"dc:publisher","label":"Institution","values":["Università degli Studi di Milano"]},{"key":"dc:relation","label":"Dc Relation","values":["numberofpages:64"]},{"key":"dc:type","label":"Dc Type","values":["info:eu-repo/semantics/doctoralThesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Settore MEDS-10/B - Malattie infettive"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["info:eu-repo/semantics/openAccess"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://hdl.handle.net/2434/1157078","http://dx.doi.org/10.13130/bono-valeria_phd2025-03-25","10.13130/bono-valeria_phd2025-03-25"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Primary HIV infection (PHI) plays a pivotal role in establishing the viral reservoir, leading to persistent immune activation and inflammation despite combination antiretroviral therapy (cART). While cART has transformed HIV into a manageable chronic condition, it remains unable to eradicate the virus or fully restore immune homeostasis. This study explores two critical aspects of HIV management: (i) the impact of early cART initiation during PHI on inflammation, immune activation, and microbial translocation, and (ii) the effects of innovative therapeutic strategies, including dual cART regimens and long-acting injectable treatments, on immune regulation and T-cell homeostasis. The research is structured around three key objectives: (1) investigating the HIV reservoir, circulating Th1/Th2 cytokines, gut integrity, and microbial translocation in individuals with PHI and chronic HIV infection (CHI) before and after cART initiation; (2) assessing immune parameters, gut barrier dysfunction, and mitochondrial stress in PLWH switching from triple to dual INSTI-based cART; and (3) evaluating T-cell homeostasis and activation in virally suppressed individuals transitioning to the long-acting injectable regimen cabotegravir plus rilpivirine (CAB+RPV). By providing deeper insights into how different treatment strategies affect immune activation and inflammation, this study aims to refine therapeutic approaches and mitigate long-term complications in people living with HIV."]},{"key":"dc:title","label":"Title","values":["INFLAMMATORY AND T-CELL HOMEOSTASIS PARAMETERS IN DUAL AND TRIPLE COMBINATION ANTIRETROVIRAL THERAPY (CART) FOR HIV INFECTION"]}]}],"canonical_facts":{"dc:contributor":["tutor: C. Tincati : revisori: M. Lichtner","G. Madeddu; coordinatore: M. Clerici","C. Sforza","V. Bono","TINCATI, CAMILLA","SFORZA, CHIARELLA","CLERICI, MARIO SALVATORE"],"dc:creator":["BONO, VALERIA"],"dc:date":["2025-03-25"],"dc:description":["Primary HIV infection (PHI) plays a pivotal role in establishing the viral reservoir, leading to persistent immune activation and inflammation despite combination antiretroviral therapy (cART). While cART has transformed HIV into a manageable chronic condition, it remains unable to eradicate the virus or fully restore immune homeostasis. This study explores two critical aspects of HIV management: (i) the impact of early cART initiation during PHI on inflammation, immune activation, and microbial translocation, and (ii) the effects of innovative therapeutic strategies, including dual cART regimens and long-acting injectable treatments, on immune regulation and T-cell homeostasis. The research is structured around three key objectives: (1) investigating the HIV reservoir, circulating Th1/Th2 cytokines, gut integrity, and microbial translocation in individuals with PHI and chronic HIV infection (CHI) before and after cART initiation; (2) assessing immune parameters, gut barrier dysfunction, and mitochondrial stress in PLWH switching from triple to dual INSTI-based cART; and (3) evaluating T-cell homeostasis and activation in virally suppressed individuals transitioning to the long-acting injectable regimen cabotegravir plus rilpivirine (CAB+RPV). By providing deeper insights into how different treatment strategies affect immune activation and inflammation, this study aims to refine therapeutic approaches and mitigate long-term complications in people living with HIV."],"dc:identifier":["https://hdl.handle.net/2434/1157078","http://dx.doi.org/10.13130/bono-valeria_phd2025-03-25","10.13130/bono-valeria_phd2025-03-25"],"dc:language":["eng"],"dc:publisher":["Università degli Studi di Milano"],"dc:relation":["numberofpages:64"],"dc:rights":["info:eu-repo/semantics/openAccess"],"dc:subject":["Settore MEDS-10/B - Malattie infettive"],"dc:title":["INFLAMMATORY AND T-CELL HOMEOSTASIS PARAMETERS IN DUAL AND TRIPLE COMBINATION ANTIRETROVIRAL THERAPY (CART) FOR HIV INFECTION"],"dc:type":["info:eu-repo/semantics/doctoralThesis"]},"updated_at":"2026-07-27T20:19:05Z"}